Cargando…

ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden

Detalles Bibliográficos
Autores principales:	Wang, Yu-Hung, Lin, Chien-Chin, Lee, Sze-Hwei, Tsai, Cheng-Hong, Wu, Shan-Ju, Hou, Hsin-An, Huang, Tai-Chung, Kuo, Yuan-Yeh, Yao, Ming, Chang, Koping, Lin, Chung-Wu, Lin, Yun-Chu, Tien, Fen-Ming, Chou, Wen-Chien, Tang, Jih-Luh, Tien, Hwei-Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550588/ https://www.ncbi.nlm.nih.gov/pubmed/33046688 http://dx.doi.org/10.1038/s41408-020-00364-5

Ejemplares similares

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

JAK2(V617F) allele burden in polycythemia vera: burden of proof
por: Moliterno, Alison R., et al.
Publicado: (2023)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

JAK2 Exon 14 Skipping in Patients with Primary Myelofibrosis: A Minor Splice Variant Modulated by the JAK2-V617F Allele Burden
por: Catarsi, Paolo, et al.
Publicado: (2015)

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
por: Tognon, Raquel, et al.
Publicado: (2012)

The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression
por: Malara, Alessandro, et al.
Publicado: (2022)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
por: Yönal-Hindilerden, İpek, et al.
Publicado: (2023)

PD‐L1 expression in megakaryocytes and its clinicopathological features in primary myelofibrosis patients
por: Lee, Sze‐Hwei, et al.
Publicado: (2021)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

The relevance of a low JAK2(V617F) allele burden in clinical practice: a monocentric study
por: Perricone, Margherita, et al.
Publicado: (2017)

Relationship of JAK2 (V617F) Allelic Burden with Clinico-Haematological Manifestations of Philadelphia-Negative Myeloproliferative Neoplasms
por: Yow, Ka Shing, et al.
Publicado: (2020)

The Combination of JAK2V617F Allele Burden and WT1 Expression can Be Helpful in Distinguishing the Subtype of MPN Patients
por: Wu, Sanyun, et al.
Publicado: (2023)

Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice
por: Akada, Hajime, et al.
Publicado: (2014)

The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm
por: Park, Sang Hyuk, et al.
Publicado: (2013)

Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
por: Vannucchi, Alessandro Maria, et al.
Publicado: (2017)

Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: A study from India
por: Sazawal, Sudha, et al.
Publicado: (2019)

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS
por: Hwang, Yun Hui, et al.
Publicado: (2023)

Correlations between Janus Kinase 2 V617F Allele Burdens and Clinicohematologic Parameters in Myeloproliferative Neoplasms
por: Ha, Jung-Sook, et al.
Publicado: (2012)

Combination therapy with interferon and JAK1-2 inhibitor is feasible: Proof of concept with rapid reduction in JAK2V617F-allele burden in polycythemia vera
por: Bjørn, M.E., et al.
Publicado: (2014)

A comparison of qPCR and ddPCR used for quantification of the JAK2 V617F allele burden in Ph negative MPNs
por: Link-Lenczowska, Dorota, et al.
Publicado: (2018)

A Comparison of Bone Marrow Morphology and Peripheral Blood Findings in Low and High Level JAK2 V617F Allele Burden
por: Babarović, Emina, et al.
Publicado: (2023)

Low JAK2 V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional CALR or MPL Gene Mutations
por: Makarik, Tatiana V., et al.
Publicado: (2021)

Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis
por: Chen, Chien-Yuan, et al.
Publicado: (2013)

Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan
por: Chen, Chien-Yuan, et al.
Publicado: (2018)

Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden
por: Kovacsovics-Bankowski, Magdalena, et al.
Publicado: (2016)

Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing
por: Ferrer-Marín, Francisca, et al.
Publicado: (2013)

The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model
por: Hsu, Yueh-Chwen, et al.
Publicado: (2017)

Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection
por: Zapparoli, Giada V, et al.
Publicado: (2013)

P726: TET2 ALLELIC BURDEN IMPRINTS A CONTEXT-DEPENDENT PROGNOSTIC SIGNIFICANCE OF ASXL1 MUTATION IN CHRONIC MYELOMONOCYTIC LEUKAEMIA
por: Wang, Yu-Hung, et al.
Publicado: (2023)

Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
por: Chen, Jui‐Che, et al.
Publicado: (2021)

Intracranial hemorrhage in adult patients with hematological malignancies
por: Chen, Chien-Yuan, et al.
Publicado: (2012)

High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia
por: Lee, Sze-Hwei, et al.
Publicado: (2017)

PB2193: JAK2 V617F MUTATION BURDEN DETECTION AND RELATIONSHIP WITH LABORATORY CHARACTERISTICS IN MYELOPROLIFERATIVE NEOPLASMS
por: MA, Xuefei, et al.
Publicado: (2023)

High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia
por: Chen, Chien-Yuan, et al.
Publicado: (2015)

Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for JAK2 V617F Allele Mutational Burden Assessment in Myeloproliferative Neoplasms: A Retrospective Study
por: La Rocca, Francesco, et al.
Publicado: (2020)

Functional association of NR4A3 downregulation with impaired differentiation in myeloid leukemogenesis
por: Lin, Shih-Chiang, et al.
Publicado: (2022)

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2014)

Allelic Expression Imbalance of JAK2 V617F Mutation in BCR-ABL Negative Myeloproliferative Neoplasms
por: Kim, Hye-Ran, et al.
Publicado: (2013)

Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o6s0nv06lohtonemlq04r0h173